First Commercial Pancreas Cancer Treatment With The OncoSil™ Device In Spain
Sydney, Australia – 13 April 2022: OncoSil Medical Ltd (ASX: OSL) (OncoSil or the Company), a medical device company focused on localised treatments for patients with locally advanced pancreatic cancer, is pleased to announce the first commercial treatment of the OncoSil™ device in Europe, with the procedure being performed at The Hospital Universitario de Fuenlabrada, located in Madrid, Spain.
The OncoSil team have fully trained 10 hospital sites in Spain for the implantation of the OncoSil™ device. Hospitals in Spain are permitted to negotiate a departmental budget for a specified number of treatments annually. Procurement of the OncoSil™ device is done via a formal tender process for each hospital. The
sales team in Spain is currently working with other trained hospitals to facilitate the tender process to enable greater patient access to the OncoSil™ treatment in various regions throughout Spain.
The Head of Nuclear Medicine at The Hospital Universitario de Fuenlabrada in Madrid, Dr Virginia Peiro said: “I am very proud to be involved at Fuenlabrada in the treatment of locally advanced pancreatic cancer patients with this new targeted radionuclide therapy.”
OncoSil’s CEO and Managing Director, Mr Nigel Lange said: “We are excited to achieve this important milestone for the first commercial patient being treated in Europe. COVID-19 has resulted in lengthy delays in gaining access to hospitals for the OncoSil team to provide training which is of vital importance when treating patients with this new therapy. As restrictions are now beginning to ease, our team have been able to train more hospitals and work with Key Opinion Leaders on the benefits of the OncoSil™ device for patients with locally advanced pancreatic cancer. We look forward to the OncoSil™ device becoming more accessible to patients throughout Spain and subsequently other European countries, to maximise the benefit from this novel treatment. Overall, following our recent success in Germany, we expect the momentum of OncoSil™ device sales to continue improving over the course of the current year.”